v3.22.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 3,734,646 $ 12,264,736
Unbilled receivable 276,631 441,721
Right-of-use asset 10,251 24,721
Prepaid expenses and other current assets 3,173,246 2,931,415
Total current assets 7,194,774 15,662,593
Property and equipment, net
Deferred financing costs 82,819
Other assets 671,423 754,756
Total assets 7,949,016 16,417,349
Current liabilities:    
Accounts payable 3,048,037 301,104
Accrued expenses and other liabilities 2,670,591 3,407,533
Lease liability 10,313 24,874
Notes payable and accrued interest ($2,519,539 and $12,358,886 at fair value at June 30, 2022 and December 31, 2021, respectively) 2,519,539 12,748,155
Total current liabilities 8,248,480 16,481,666
Long-term liabilities:    
Notes payable, net of current portion 137,317 4,440,951
Other long-term liabilities 360,797 3,652,790
Total liabilities 8,746,594 24,575,407
Commitments and contingencies (Note 6)
Stockholders’ deficit    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2022 (unaudited) and December 31, 2021
Common stock, $0.0001 par value, 150,000,000 shares authorized; 35,550,034 and 24,662,904 shares issued at June 30, 2022 (unaudited) and December 31, 2021, respectively; 35,530,279 and 24,643,149 shares outstanding at June 30, 2022 (unaudited) and December 31, 2021, respectively 3,553 2,464
Additional paid-in capital 95,016,354 77,964,860
Accumulated deficit (95,511,543) (85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ deficit (491,636) (7,878,243)
Noncontrolling interests in stockholders’ deficit (305,942) (279,815)
Total stockholders’ deficit (797,578) (8,158,058)
Total liabilities and stockholders’ deficit $ 7,949,016 $ 16,417,349

Source